Last synced on 25 January 2026 at 3:41 am

High Performance Liquid Chromatography For Cyclosporine

Page Type
Product Code
Regulation Medical Specialty
Chemistry
Review Panel
Toxicology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
862.1235
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Third Party Eligible

CFR § 862.1235 Cyclosporine test system

§ 862.1235 Cyclosporine test system.

(a) Identification. A cyclosporine test system is a device intended to quantitatively determine cyclosporine concentrations as an aid in the management of transplant patients receiving therapy with this drug. This generic type of device includes immunoassays and chromatographic assays for cyclosporine.

(b) Classification. Class II (special controls). The special control is “Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA.” See § 862.1(d) for the availability of this guidance document.

[67 FR 58329, Sept. 16, 2002]

High Performance Liquid Chromatography For Cyclosporine

Page Type
Product Code
Regulation Medical Specialty
Chemistry
Review Panel
Toxicology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
862.1235
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Third Party Eligible

CFR § 862.1235 Cyclosporine test system

§ 862.1235 Cyclosporine test system.

(a) Identification. A cyclosporine test system is a device intended to quantitatively determine cyclosporine concentrations as an aid in the management of transplant patients receiving therapy with this drug. This generic type of device includes immunoassays and chromatographic assays for cyclosporine.

(b) Classification. Class II (special controls). The special control is “Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA.” See § 862.1(d) for the availability of this guidance document.

[67 FR 58329, Sept. 16, 2002]